Synthaverse S.A. (6NQ.F)
- Previous Close
1.0280 - Open
0.9820 - Bid 1.0300 x --
- Ask 1.1920 x --
- Day's Range
0.9820 - 1.0400 - 52 Week Range
0.6335 - 1.3150 - Volume
400 - Avg. Volume
24 - Market Cap (intraday)
79.384M - Beta (5Y Monthly) 1.28
- PE Ratio (TTM)
52.00 - EPS (TTM)
0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company's prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50 and BCG 100 products for treating superficial (non-muscle invasive) bladder tumor; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerolfor is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma. In addition, the company provides reagents, such as horse serum, bovine serum, calf serum, trypsin, PBS fluid, hanks fluid, parker's fluid, Eagle 1959 medium, Rpmi 1640 medium, and Ogawa medium, as well as pseudo cholinesterase, Ox fibrinogen, and rabbit complements. The company was formerly known as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. and changed its name to Synthaverse S.A. in July 2023. The company was founded in 1944 and is based in Lublin, Poland.
www.synthaverse.plRelated News
Performance Overview: 6NQ.F
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6NQ.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6NQ.F
Valuation Measures
Market Cap
78.47M
Enterprise Value
94.20M
Trailing P/E
63.35
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.32
Price/Book (mrq)
2.78
Enterprise Value/Revenue
1.61
Enterprise Value/EBITDA
6.33
Financial Highlights
Profitability and Income Statement
Profit Margin
8.12%
Return on Assets (ttm)
2.45%
Return on Equity (ttm)
4.36%
Revenue (ttm)
58.61M
Net Income Avi to Common (ttm)
4.76M
Diluted EPS (ttm)
0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
2.17M
Total Debt/Equity (mrq)
62.19%
Levered Free Cash Flow (ttm)
-112.07M
Company Insights: 6NQ.F
6NQ.F does not have Company Insights